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MEDICARE COVERAGE SOUGHT
FOR ALLO TRANSPLANTS FOR MDS
Allogeneic stem cell transplants for
myelodysplastic syndrome (MDS)
would be consistently eligible for
Medicare reimbursement if the federal
government accepts a formal request
that has been submitted by ASBMT
and the National Marrow Donor Pro-
gram (NMDP), together with 10 other
organizations.
‘‘We believe that the body of evi-
dence supports a coverage policy
that ensures that Medicare beneficia-
ries diagnosed with MDS have access
to allogeneic HCT,’’ said a letter asking
for a national coverage determina-
tion, submitted Sept. 21 to the
Centers for Medicare and Medicaid
Services (CMS).
Medicare patients age 65 and older
represent 80 percent of the total pop-
ulation diagnosed with MDS in the
United States. For some of these
patients, allogeneic hematopoietic
cell transplantation (HCT) is the only
available curative therapy and the
only treatment that can prevent cer-
tain death from the disease.
Currently some Medicare regional
contractors for Part A (hospital) and
Part B (physician) services do reim-
burse for stem cell transplants for
MDS, but coverage is inconsistent
across the country. Each instance
may require extensive justification of
the efficacy of allogeneic transplants
for MDS. Without an explicit and
well-defined national policy, hospitals
often are reluctant to extend HCT ser-
vices to Medicare beneficiaries who
would benefit. A national coverage
determination would guarantee ap-
propriate and timely access to curative
treatment for MDS under the federal
health programs.
After months of gathering evidence
to document a request, ASBMT and
NMDP met with CMS representatives
in February for preliminary discussion
about applying for a national cover-
age determination. The outcomewas encouraging enough to proceed
with assembling a coalition of organi-
zations to submit a formal request.
Those joining in the petition are:
AABB (formerly the American Associa-
tion of Blood Banks), American Can-
cer Society, American Cancer Society
Cancer Action Network, American
Society for Hematology, American
Society of Clinical Oncology, Aplastic
Anemia and MDS, International Foun-
dation, Blood & Marrow Transplant In-
formation Network, National Bone
Marrow Transplant Link, The Bone
Marrow Foundation and The Leuke-
mia & Lymphoma Society.
Included in the documentation
submitted to CMS was an evidence-
base review of the scientific and med-
ical literature published in February
this year, part of the ongoing series
of comprehensive reviews of indica-
tions for HCT that ASBMT has spon-
sored and NMDP has supported over
the past 10 years. Each review is con-
ducted by a multidisciplinary panel of
experts.
Another important part of the docu-
mentation was a study conducted by
the Center for International Blood and
Marrow Transplant Research (CIBMTR)
showing that outcomes for older
adults undergoing allogeneic HCT
for MDS are not significantly different
than those of younger adults, even af-
ter adjusting for multiple risk factors.
The analysis, presented last year at
the American Society of Hematology
annual meeting, revealed no statisti-
cally significant impact of age on
transplant-related mortality, relapse,
leukemia-free survival or overall sur-
vival. The report has been submitted
for publication.
‘‘The study involved 551 MDS
patients in the CIBMTR database
who were transplanted from 1995
to 2005,‘‘ said Claudio Anasetti, MD,
ASBMT president. ’’The analysis con-
cluded that age by itself should not
be a limiting factor for proceedingwith allogeneic HCT in older MDS
patients.’’
MDS becomes more common as
people age. In the United States, the
overall incidence of MDS is estimated
at 3.3 per 100,000, but the incidence
in patients over 70 is between 15 and
50 per 100,000, according to recently
published epidemiological data.OPINIONS OF ASBMT MEMBERS
VARY ON BOARD CERTIFICATION
ASBMT members are not of a single
mind about board certification. They
find some aspects of BMT clinician cer-
tification appealing, but other aspects
troubling.
Member opinions about certifica-
tion and the training of BMT fellows
were sampled in an online survey in
September. About a third (32%) of
the society’s physician members com-
pleted the survey. Among those re-
sponding, 63% treat adult patients,
28% pediatric patients and 9% both.
Half of the respondents said they prac-
ticed in a center that has a BMT train-
ing program, and half did not.
The respondents were divided on
whether the society should pursue
certification for BMT clinicians: 38%
agreed, 35% disagreed, and 27%
were ambivalent or not sure.
There was consensus, however, on
several related questions:
 By a margin of nearly 2 to 1, mem-
bers agreed with the statement
that ‘‘Care of BMT patients in the
United States would be improved
if BMT physicians were board
certified.’’
 But by a margin of more than 2 to
1, members also agreed with the
statement that ‘‘BMT physicians
are burdened enough with current
licensing and certification require-
ments. We don’t need yet another
certification.’’
Many of the society’s members said
that board certification might compli-
cate recruitment of young physicians
at a time when a severe shortage of145
146 ASBMT Newstransplant clinicians is forecast. By
a margin of nearly 3 to 1, members
agreed with the statement that ‘‘BMT
board certification would limit physi-
cian entry into the BMT field.’’
Members were divided on the ef-
fect of board certification on physician
compensation–34% said it would be
beneficial, 28% thought it would
have little effect, and 39% were not
sure.
Certification of BMT clinicians
almost certainly would need to be
coupled with the development of
training programs recognized by the
Accreditation Council for Graduate
Medical Education. By a margin of
more than 3 to 1, members agreed
that clinicians entering the BMT field
need additional training after a
hematology/oncology fellowship. A
majority of respondents felt that 6-12
months of dedicated BMT training is
necessary for trainees entering BMT
careers.
Some members expressed concern
that current training of young BMT at-
tending physicians is not optimal.
Members were asked ‘‘In your experi-
ence, based on their first months on
the job as an attending physician,
how would you characterize the cur-
rent training of fellows pursuing BMT
as a career?’’
Thirty-four percent said that they
felt training was barely adequate or in-
adequate. Many commented that this
is because most fellowship programslack the ability to offer robust BMT
training.
‘‘The large response to the online
survey – a third of our physician mem-
bers – speaks to the level of interest in
the certification topic,’’ said Linda
Burns, MD, chair of the ASBMT Task
Force on Board Certification. ‘‘Many
members accepted our invitation to
write additional comments that have
been quite helpful to the task force
in its deliberations.’’ The task force
presented its recommendations to
the ASBMT officers and directors in
December.
Dr. Burns is based at the University
of Minnesota. Other members of the
task force are Stephan Grupp, MD,
PhD, Children’s Hospital of Philadel-
phia; Mark Juckett, MD, University of
Wisconsin; Shakila Khan, MD, Mayo
Clinic-Rochester; Vivek Roy, MD,
Mayo Clinic-Jacksonville; and Thomas
Shea, MD, University of North
Carolina.STANLEY RIDDELL TO PRESENT
DONNALL THOMAS LECTURE
Stanley R. Riddell, MD, of the Fred
Hutchinson Cancer Research Center
and the University of Washington
School of Medicine will present the
13th annual E. Donnall Thomas Lec-
ture at the 2010 BMT Tandem Meet-
ings, Feb. 24-28 in Orlando.His presentation, ‘‘Therapeutic T-
cells: The End of the Long Beginning,’’
will be on Friday, Feb. 26.ORLANDO MEETING TO HAVE FOUR
‘MEET THE PROFESSOR’ LUNCHES
Fellows and junior faculty attend-
ing the 2010 BMT Tandem Meetings
will have an opportunity for informal
discussions with experts in BMT
patient management. Four lunch ses-
sions will feature authorities leading
case-based discussions:
 Mismatched Transplants – Claudio
Anasetti, MD, Moffitt Cancer Center
 Low Grade Lymphoma – Philippe
Armand, MD, PhD, Dana-Farber
Cancer Institute
 cGVHD – Stephanie Lee, MD, MPH,
Fred Hutchinson Cancer Research
Center
 Pediatric CBT – Peter Shaw, MD,
Children’s Hospital at Westmead
Because of the success of the two
‘‘Meet the Professor’’ lunches at last
year’s BMT Tandem Meetings, the
number of lunches has been doubled
to four this year.
The sessions are being developed
by the co-chairs of the BMT Tandem
Meetings Organizing Committee:
Jeffrey S. Szer, MD, of the Royal
Melbourne Hospital and Joseph
Antin, MD, of the Dana-Farber Cancer
Institute.
The sign-up for the lunches will be
at the meeting registration desk.
